The acquisition will help ADQ to boost its healthcare and life sciences portfolio and enhance its life sciences capabilities in sterile injectables and broader pharmaceutical services divisions
ADQ to acquire Turkey’s sterile injectable products producer Birgi Mefar Group (BMG). (Credit: ADQ)
Abu Dhabi-based investment and holding company ADQ has agreed to acquire Turkey-based sterile injectable products producer Birgi Mefar Group (BMG).
BMG is a producer of sterile injectable products, including vials and pre-filled syringes used for vaccines, as well as primary packaging ampoules and vials for other sterile injectables.
BMG has a presence in more than 30 countries, including markets in Europe and Asia with more than 50 years of expertise.
The acquisition will help ADQ to boost its healthcare and life sciences portfolio and enhance its life sciences capabilities in sterile injectables and broader pharmaceutical services divisions.
ADQ Healthcare & Life Sciences Portfolio executive director Fahad Al Qassim said: “BMG’s diversified offering and manufacturing capabilities make the company a strategic addition to our growing portfolio as we continue to shape the UAE’s healthcare & life sciences platform.
“Turkey is an important market for our investments, and BMG brings with it a strong presence throughout the pharmaceutical supply chain, from drug development and manufacturing to packaging and cold chain distribution.
“With this integrated capability, we believe it can enhance local expertise and build on the UAE’s ability to manufacture and distribute quality health products as the region’s leading pharmaceutical hub.”
The deal is a part of ADQ’s efforts in the UAE to create a fully integrated healthcare and life sciences platform.
It will give ADQ access to a rapidly developing market of injectables and high-value therapies like vaccines, as well as a diverse customer base spanning from huge multinationals to small and regional businesses.
BMG will also become part of ADQ’s Healthcare and Life Science portfolio, which aims to improve production, distribution, and commercialisation capabilities, including the provision of sterile health products and injectable solutions.
Earlier this year, ADQ acquired Acino, a Swiss-based pharmaceutical manufacturer with a presence in more than 90 countries.
The deal is subject to standard closing conditions, which include regulatory approvals.